205 Protein Engineering III: Therapeutics I

Description:
This session will focus on protein engineering for therapeutic applications, with an emphasis on emerging topics and recent successes. Potential areas of interest include, but are not limited to, (1) advances in protein-based therapeutics, (2) proteins for cell targeting and imaging, and (3) proteins involved in disease pathology.

Sponsor:
Bioengineering

Chair:
Laura Segatori
Email: segatori@rice.edu

Co-Chair:
Yvonne Y. Chen
Email: yvonne_chen@hms.harvard.edu


Papers:

3:15 PM
Break

3:33 PM
(205b) Production of the Trimeric Influenza Hemagglutinin Stem Domain for Potentially Broadly Protective Influenza Vaccines
Yuan Lu and James R. Swartz

3:51 PM
(205c) Logical Computation By Chimeric Antigen Receptors Increases Tumor-Targeting Capability of Engineered T Cells
Yvonne Chen

4:09 PM
(205d) Engineered Mono-Specific Proteins As In Vivo Imaging Agents That Target Tumor Vasculature
Shiven Kapur, Adam P. Silverman, Gerald M. Cherf, Anne Ye and Jennifer R. Cochran

4:27 PM
(205e) Advances in Engineering a Human Cystathionine-γ-Lyase for Systemic L‑Methionine Depletion Cancer Therapy
Olga M. Paley, Wei-Cheng Lu, Jian Hu, Nai-Kong Cheung, Everett M. Stone and George Georgiou

4:45 PM
(205f) A Suite of Anti-Fibroblast Activation Protein-Alpha Antibodies for Targeting the Tumor Microenvironment
James A. Van Deventer, Saravanan Rajan, Sachdev Sidhu and K. Dane Wittrup

5:03 PM
(205g) Engineering Ligand Biophysics to Enhance Tumor Targeting
Brett Case and Benjamin J. Hackel

5:21 PM
(205h) Selective Inhibition of Weak-Affinity Epitope-IgE Interactions Via Heterobivalent Inhibitor Design Prevents Mast Cell Degranulation
Michael W. Handlogten, Tanyel Kiziltepe, Ana Serezani, Mark Kaplan and Basar Bilgicer
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division
<< Previous Session | Next Session >>